2102 Blood Biomarker Screening for Cervical Spondylotic Myelopathy: Markov-Based Cost-Effectiveness Analysis

View at publisher Summarise with VIRAT
Authors: Ayesha Akbar Waheed, Armani Manov, Hanish Polavarapu, Aditya Mittal, Sameer Agnihotri, David Hamilton, Kamil W. Nowicki, Nitin Agarwal
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Cervical Spondylotic Myelopathy (CSM) is a common degenerative spine condition with significant morbidity, but early diagnosis remains challenging. Current diagnostic approaches rely on clinical assessment and advanced imaging, which can be costly and may delay treatment. METHODS: Markov decision analytic models were created using MATLAB to simulate CSM management pathways within the U.S. healthcare system. The model compared standard of care (SOC) versus a biomarker strategy incorporating the blood test. Probabilities and costs were obtained from literature and national databases. Quality-adjusted life years (QALYs) were used to assess outcomes. The model was run over 50 cycle-years with subgroup analyses performed for patients with a high probability of developing CSM. RESULTS: The biomarker arm kept substantially more patients free of lasting disability: projected disability prevalence dropped from 25% to 18% at 25 years (-28%) and from 27% to 23% at 50 years (-16%). For patients with a high probability of developing CSM, the SOC pathway cost $26,501.66 and yielded 21.20 QALYs, while the biomarker strategy cost $33,127.07 and yielded 22.53 QALYs. The incremental cost was $6,625.41 with incremental QALYs of 1.3251, resulting in an incremental cost-effectiveness ratio (ICER) of $5,000.00 per QALY gained. Compared to standard willingness-to-pay thresholds, this ICER represents only 10% of the $50,000 threshold, 5% of the $100,000 threshold, and 2.5% of the $200,000 threshold, indicating exceptional cost-effectiveness. CONCLUSIONS: A blood biomarker test would deliver exceptional value for patients with CSM. This approach proves financially justifiable and would enable physicians to intervene earlier in the disease progression. Patients experience meaningful improvements in quality of life compared to conventional diagnostic pathways, with better long-term outcomes. The low ICER makes this biomarker strategy a promising and feasible addition to clinical practice.

Fields of Study & Subjects

Cervical and Thoracic Myelopathy Health Systems Economic Evaluations Quality of Life Musculoskeletal pain and rehabilitation

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
271–272
Publication date
26 March 2026
Language
EN